Dr. Peter Ruane, MD
Infectious Disease (Infectious Disease Physician)
5901 W Olympic Blvd, Suite 401
Los Angeles, CA 90036
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 48
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 325
Licensed in California since 1986, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
CA license A42947 (first issued 1986; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cedars-Sinai Medical Center Los Angeles, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 325
- Services billed
- 11,180
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 471 | 225 |
| Blood test, basic group of blood chemicals (calcium, total) | 443 | 215 |
| Liver function blood test panel | 437 | 214 |
| Blood test, lipids (cholesterol and triglycerides) | 435 | 223 |
| Detection test by nucleic acid for hiv-1 virus, quantification | 401 | 181 |
| Magnesium level | 398 | 203 |
| Phosphate level | 397 | 199 |
| Established patient office or other outpatient visit, 30-39 minutes | 354 | 173 |
| Established patient office or other outpatient visit, 40-54 minutes | 345 | 182 |
| Established patient office or other outpatient visit, 20-29 minutes | 231 | 124 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Descovy (emtricitabine/tenofov alafenam) | 78 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Los Angeles, CA | 44 |
| Gabapentin Other prescribers in Los Angeles, CA | 42 |
| Prezcobix (darunavir/cobicistat) | 36 |
| Tamsulosin Hcl Other prescribers in Los Angeles, CA | 35 |
| Tivicay (dolutegravir sodium) | 35 |
| Rosuvastatin Calcium Other prescribers in Los Angeles, CA | 33 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 28 |
| Odefsey (emtricitab/rilpiviri/tenof ala) | 28 |
| Isentress (raltegravir potassium) | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 94 payments worth $2,646 in total to this clinician.
| Viiv Healthcare Company | $1,131 |
|---|---|
| Gilead Sciences, Inc. | $398 |
| Amgen Inc. | $197 |
| Napo Pharmaceuticals Inc | $171 |
| Merck Sharp & Dohme LLC | $157 |
| EMD Serono, Inc. | $142 |
| AstraZeneca Pharmaceuticals LP | $133 |
| Bausch Health US, LLC | $112 |
| Food and Beverage | $2,646 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $839,321 in research payments for these studies, mostly to the institutions running them.
- A phase 2B single arm, repeat dose study to evaluate the pharmacokinet
Viiv Healthcare Company - A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Tra…
Gilead Sciences, Inc. - A phase iiib, randomized, multicenter, parallel-group, non-inferiority
Viiv Healthcare Company - A phase 3B, open label, randomized, standard-of-care control arm, mult
Viiv Healthcare Company - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: …
Gilead Sciences, Inc. - Captivate (cab la for prep utilization outcomes experience)
Viiv Healthcare Company - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalim…
AbbVie Inc. - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
AbbVie Inc. · Terminated · NCT06032546
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.